ChiCTR2300069377 版本V1.1 版本创建时间2023/05/24 20:25:10 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300069377 

最近更新日期:

Date of Last Refreshed on:

2023-03-15 09:15:16 

注册时间:

Date of Registration:

2023-03-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

比较仅含A2 β-酪蛋白的脱脂奶粉与常规含A1和A2 β-酪蛋白的脱脂奶粉对老年人度认知障碍的影响:一项双盲、随机、轻对照试验

Public title:

Comparing the effect of powdered skim milk containing A2 β-casein only versus conventional powdered skim milk containing A1 and A2 β-caseins on mild cognitive impairment in older adults: A two-phase, double-blind, randomized, controlled trial

注册题目简写:

A2脱脂奶粉对老年人轻度认知障碍的影响研究

English Acronym:

Effect of A2 skimmed milk powder on mild cognitive impairment in the elderly

研究课题的正式科学名称:

比较仅含A2 β-酪蛋白的脱脂奶粉与常规含A1和A2 β-酪蛋白的脱脂奶粉对老年人度认知障碍的影响:一项双盲、随机、轻对照试验

Scientific title:

Comparing the effect of powdered skim milk containing A2 β-casein only versus conventional powdered skim milk containing A1 and A2 β-caseins on mild cognitive impairment in older adults: A two-phase, double-blind, randomized, controlled trial

研究课题代号(代码):

Study subject ID:

A2MC-G190549358

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙彬 

研究负责人:

张克明 

Applicant:

Bin Sun 

Study leader:

Keming Zhang 

申请注册联系人电话:

Applicant telephone:

15210594168

研究负责人电话:

Study leader's
telephone:

15522211995

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sunbin@esmile.com.cn

研究负责人电子邮件:

Study leader's E-mail:

zzkkmmxx@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

北京易思迈科技有限责任公司

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区广顺南大街15号院2号楼嘉美中心写字楼817

研究负责人通讯地址:

天津市西青区昌陵路88号

Applicant address:

Office 817, Jiamei Center, Building 2, Yard 15, Guangshun South Street, Chaoyang District, Beijing

Study leader's address:

88 Changling Road, Xiqing District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

100020

研究负责人邮政编码:

Study leader's postcode:

300380

申请人所在单位:

北京易思迈科技有限责任公司

Applicant's institution:

Beijing Esmile Technology Co., LTD

研究负责人所在单位:

天津中医药大学第一附属医院

Affiliation of the Leader:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TYLL2023[K]字008

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津中医药大学第一附属医院医学伦理委员会

Name of the ethic committee:

IRB of The First Teaching Hospital of Tianjin University of TCM

伦理委员会批准日期:

Date of approved by ethic committee:

2023-02-08 00:00:00

伦理委员会联系人:

郑子琦

Contact Name of the ethic committee:

Ziqi Zheng

伦理委员会联系地址:

天津市鞍山西道314号

Contact Address of the ethic committee:

314 Anshan West Road, Tianjin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

022-27986258

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津中医药大第一附属医院

Primary sponsor:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

天津市西青区昌陵路88号

Primary sponsor's address:

88 Changling Road, Xiqing District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学总医院

具体地址:

天津市和平区鞍山道154号

Institution
hospital:

Tianjin Medical University General Hospital

Address:

154 Anshan Road, Heping District, Tianjin

国家:

中国

省(直辖市):

吉林

市(区县):

长春

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

吉林省人民医院

具体地址:

吉林省长春市工农大街1183号

Institution
hospital:

Jilin Provincial People's Hospital

Address:

1183 Gongnong Street, Changchun, Jilin Province, China

经费或物资来源:

a2牛奶有限公司

Source(s) of funding:

The a2 Milk Company

研究疾病:

轻度认知障碍  

Target disease:

Mild cognitive impairment

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较仅含A2 β-酪蛋白的脱脂奶粉与常规含A1和A2 β-酪蛋白的脱脂奶粉对认知障碍的影响。  

Objectives of Study:

Compare the effect of the skimmed milk powder only containing A2-β casein to the skimmed milk powder containing A1 and A2 β- casein on cognitive impairment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 65~75周岁的老年人;
2. 主诉记忆减退至少6个月;
3. 基于中文版简易精神状态检查表(MMSE),认知能力得分低于根据年龄和受教育程度设定的边界值:0年教育时MMSE得分≤17分;教育年限不超过6年的MMSE得分≤20分;学历超过6年的MMSE得分≤24分;
4. 生活和社交功能降低:日常生活活动(ADL)得分≤18分;
5. 未达到痴呆诊断标准(精神疾病诊断和统计手册第四版)、阿尔茨海默病(国家中风神经疾病语言障碍研究所和阿尔茨海默病及相关疾病协会);没有精神障碍、脑损伤或其他可能导致认知障碍的身体障碍;
6. 同意在本研究期间不参与另一项干预性临床研究;
7. 签署知情同意书。

Inclusion criteria

1. Adults aged 65-75 years;
2. Complaint of memory loss for more than 6 months;
3. Base on the Chinese version of Mini Mental State Examination (MMSE), cognitive ability score is lower than the standard cut-off value according to age and education levels: MMSE score≤ 17 points if years of education is 0 year; ≤ 20 points if 6 years or less of education; ≤ 24 points if more than 6 years of education
4. Living and social functions are reduced: activities of daily living (ADL) score ≤18;
5. Not meeting the diagnostic criteria for dementia (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition), Alzheimer Disease (National Stroke Institute for Neuropathic Speech Disorders and Association for Alzheimer Disease and Related Disorders); no mental disorder, brain damage, or other physical disorders that can lead to cognitive impairment.
6. Agreed not to participate in another interventional clinical research study during the present study;
7. Signed informed consent

排除标准:

1. 小于65周岁或大于75周岁;
2. 神经系统检查发现偏瘫、感觉障碍、失语等中枢神经系统障碍的局灶症状病史;有脑血管疾病史(包括出血性和缺血性)、颅内伤或正患有骨折;
3. 哮喘性支气管炎、严重高血压、心绞痛、严重感染;
4. 抑郁、焦虑等精神障碍;内分泌系统疾病(如甲亢、甲减、系统性红斑狼疮、类风湿性关节炎);
5. 早期、中期、晚期肿瘤;
6. 视觉、阅读、听力障碍或语言沟通困难严重影响认知功能测试;
7. 有酒精依赖史和滥用精神活性物质(如抗精神病药、苯二氮卓类、胆碱酯酶抑制剂、镇静剂)或使用影响认知功能的药物史;
8. 神经系统疾病(如帕金森病、癫痫);
9. 筛选前2周内接受抗生素治疗;
10. 筛选前4周内接受免疫抑制药物;
11. 对牛奶或奶制品过敏;
12. 已诊断的乳糖不耐受;
13. 研究人员认为不适合参与研究的其他疾病。

Exclusion criteria:

1. <65 years old or >75 years old;
2. Neurological examination showed focal signs of central nervous system disorder such as hemiplegia, dysesthesia, aphasia; history of cerebrovascular diseases (including hemorrhagic and ischemic types), internal brain trauma or fracture;
3. Asthmatic bronchitis, severe hypertension, angina and severe infection;
4. Mental disorders such as depression and anxiety; endocrine system diseases (such as hyperthyroidism, hypothyroidism, systemic lupus erythematosus, rheumatoid arthritis);
5. Newly diagnosed, progressing or advanced tumors;
6. Visual, reading, hearing impairment or language communication difficulties that significantly affect cognitive function tests;
7. History of alcohol dependence and abuse of psychoactive substances (e.g., antipsychotics, benzodiazepines, cholinesterase inhibitors, sedatives), or use of drugs that affect cognitive function;
8. Neurological diseases (e.g. Parkinson's disease, epilepsy);
9. Antibiotic treatment in previous 2 weeks;
10. Administered immunosuppressive drugs in the 4-weeks preceding screening;
11. Allergy to milk or dairy;
12. Diagnosed lactose intolerance;
13. Other diseases that investigators judged as unsuitable to participate the study.

研究实施时间:

Study execute time:

From 2023-03-15 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-03-15 00:00:00 To 2023-06-15 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

48

Group:

Intervention Group

Sample size:

干预措施:

a2脱脂奶粉

干预措施代码:

Intervention:

a2 skimmed milk powder

Intervention code:

组别:

对照组

样本量:

48

Group:

Control Group

Sample size:

干预措施:

伊利脱脂奶粉

干预措施代码:

Intervention:

Yili skimmed milk powder

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Third-class hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

tianjin

City:

单位(医院):

天津医科大学总医院 

单位级别:

天津市和平区鞍山道154号 

Institution
hospital:

Tianjin Medical University General Hospital

Level of the institution:

154 Anshan Road, Heping District, Tianjin

国家:

中国

省(直辖市):

吉林 

市(区县):

长春 

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

吉林省人民医院 

单位级别:

吉林省长春市工农大街1183号 

Institution
hospital:

Jilin Provincial People's Hospital

Level of the institution:

1183 Gongnong Street, Changchun, Jilin Province, China

测量指标:

Outcomes:

指标中文名:

轻度认知障碍测试

指标类型:

主要指标

Outcome:

Subtle Cognitive Impairment Test (SCIT)

Type:

Primary indicator

测量时间点:

基线、访视2、访视4

测量方法:

问卷

Measure time point of outcome:

Baseline, V2, V4

Measure method:

questionnaire

指标中文名:

谷胱甘肽

指标类型:

主要指标

Outcome:

glutathione

Type:

Primary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

钙卫蛋白(S100A8/A9)

指标类型:

次要指标

Outcome:

calprotectin (S100A8/A9)

Type:

Secondary indicator

测量时间点:

基线、访视2、访视3、访视4

测量方法:

粪便

Measure time point of outcome:

Baseline, V2, V3, V4

Measure method:

faecal sample

指标中文名:

髓过氧物酶

指标类型:

次要指标

Outcome:

myeloperoxidase

Type:

Secondary indicator

测量时间点:

基线、访视2、访视3、访视4

测量方法:

粪便

Measure time point of outcome:

Baseline, V2, V3, V4

Measure method:

faecal sample

指标中文名:

短链脂肪酸

指标类型:

次要指标

Outcome:

SCFAs

Type:

Secondary indicator

测量时间点:

基线、访视2、访视3、访视4

测量方法:

粪便

Measure time point of outcome:

Baseline, V2, V3, V4

Measure method:

faecal sample

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein, CRP

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

白细胞介素-1β

指标类型:

次要指标

Outcome:

IL-1β

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

白细胞介素-4

指标类型:

次要指标

Outcome:

IL-4

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

白细胞介素-8

指标类型:

次要指标

Outcome:

IL-8

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

肿瘤坏死因子-α

指标类型:

次要指标

Outcome:

TNF-α

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

分泌型免疫球蛋白E

指标类型:

次要指标

Outcome:

IgE

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

分泌型免疫球蛋白G1

指标类型:

次要指标

Outcome:

IgG1

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

分泌型免疫球蛋白G2A

指标类型:

次要指标

Outcome:

IgG2A

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

β-酪啡肽-7

指标类型:

次要指标

Outcome:

BCM-7

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

半乳糖

指标类型:

次要指标

Outcome:

galactose

Type:

Secondary indicator

测量时间点:

基线

测量方法:

尿液

Measure time point of outcome:

Baseline

Measure method:

urine sample

指标中文名:

环磷酰胺

指标类型:

次要指标

Outcome:

CTX

Type:

Secondary indicator

测量时间点:

基线、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V4

Measure method:

serum sample

指标中文名:

骨钙蛋白

指标类型:

次要指标

Outcome:

osteocalcin

Type:

Secondary indicator

测量时间点:

基线、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V4

Measure method:

serum sample

指标中文名:

指标类型:

次要指标

Outcome:

calcium

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

25-羟基维生素D3

指标类型:

次要指标

Outcome:

25-OH-D3

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V2, V4

Measure method:

serum sample

指标中文名:

握力

指标类型:

次要指标

Outcome:

grip

Type:

Secondary indicator

测量时间点:

基线、访视4

测量方法:

血清

Measure time point of outcome:

Baseline, V4

Measure method:

serum sample

指标中文名:

蒙特利尔认知评估量表

指标类型:

次要指标

Outcome:

MoCA

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

问卷

Measure time point of outcome:

Baseline, V2, V4

Measure method:

questionnaire

指标中文名:

听觉词语学习测验

指标类型:

次要指标

Outcome:

AVLT

Type:

Secondary indicator

测量时间点:

基线、访视2、访视4

测量方法:

问卷

Measure time point of outcome:

Baseline, V2, V4

Measure method:

questionnaire

指标中文名:

健康大脑衰老功能评估问卷

指标类型:

次要指标

Outcome:

Healthy Brain Ageing – Functional Assessment Questionnaire

Type:

Secondary indicator

测量时间点:

基线、访视4

测量方法:

问卷

Measure time point of outcome:

Baseline, V4

Measure method:

questionnaire

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清样本

组织:

血液

Sample Name:

serum sample

Tissue:

blood

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便样本

组织:

Sample Name:

faecal sample

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液样本

组织:

Sample Name:

urine sample

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机分配表的产生:本试验采用区组随机化法进行随机。随机分配表由专门的统计人员采用SAS软件,根据随机数字表在计算机上模拟产生。试验用药品根据随机分配表进行编码。

Randomization Procedure (please state who generates the random number sequence and by what method):

Generation of Random Grouping Table: block randomization method was used for randomization in this clinical trail. Random Grouping Table by special statisticians using SAS software, according to the Random Grouping Table on the computer simulation. Experimental milk powder are coded according to the Random Grouping Tab

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲

Blinding:

double blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结果发表后,所有原始数据均可根据对通讯作者的合理要求提供。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After publication of the study results, all raw data are available upon reasonable request to the corresponding author.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本临床试验使用病例记录表记录受试者的背景调查结果、问卷调查结果(MMSE、ADL、MoCA、AVLT和健康大脑衰老功能评估问卷)和握力,经由Epidata录入数据库。生物样本检测结果(血清、粪便、尿液)和SCIT检测结果由专业机构整理后直接导入数据库。纸质数据保留原始数据,电子数据保证数据可追溯。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Background survey results, questionnaire results (MMSE, ADL, MoCA, AVLT, and Healthy Brain Ageing – Functional Assessment Questionnaire) and grip strength were recorded using CRF and recorded via Epidata. Biological sample test results (serum, feces, urine) and SCIT test results are directly imported into the database after collated by professional institutions. Paper data retains original data, while electronic data ensures traceability.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-03-15 09:14:45